Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Cadila Healthcare&nbsp;is buzzing in trade as&nbsp;Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19. Brokergaes&nbsp;from Morgan Stanley to CLSA&nbsp;are extremely bullish on the stock on the prospect of the vaccine&nbsp;CLSA&nbsp;on Cadila&nbsp;Health: Upgraded the stock to a buy with target of Rs 650/share which is a 20% upside from Friday's close. The brokerage expects a double digit growth from the core business and says the recent correction now offers a good entry point.&nbsp;Morgan Stanley on Cadila&nbsp;Health: Though Morgan is keeping an equal weight they have a more aggressive price target at Rs 664/share as they expect the vaccine launch will provide the pivot to the stock and expect large scale&nbsp;adoption of the dose.&nbsp;

Cadila gets the right dose! Brokerages bullish after Covid 19 vaccine nod, upgrades from CLSA & Morgan 

Cadila gets the right dose! Brokerages bullish after Covid 19 vaccine nod, upgrades from CLSA, Morgan Stanley.&nbsp;

The Zycov D bullish bet

Company expects to launch the vaccine in September, pricing not yet decided.&nbsp;

Cadila Healthcare&nbsp;is buzzing in trade as&nbsp;Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19. Brokergaes&nbsp;from Morgan Stanley to CLSA&nbsp;are extremely bullish on the stock on the prospect of the vaccine&nbsp; CLSA&nbsp;on Cadila&nbsp;Health: Upgraded the stock to a buy with target of Rs 650/share which is a 20% upside from Friday's close. The brokerage expects a double digit growth from the core business and says the recent correction now offers a good entry point.&nbsp; Morgan Stanley on Cadila&nbsp;Health: Though Morgan is keeping an equal weight they have a more aggressive price target at Rs 664/share as they expect the vaccine launch will provide the pivot to the stock and expect large scale&nbsp;adoption of the dose.&nbsp;

Mindtree&nbsp;delivered strong set of Q1 numbers that beat street estimates,&nbsp; with cross currency revenue growth of 7.6% (QoQ). Morgan Stanley says there is more upside left to the stock that has seen a 150% rise in the last 1 year.Morgan Stanley Bets on Mindtree

Retain Overweight on stock, Price target of Rs 2800/share
Revenue growth and margins were stronger than expected
Deal wins of $504mn were the&nbsp;strongest the company has ever seen
Strongest ever headcount addition of 3400 in Q1

Read/Watch Also: All eyes on Infosys, how to trade the earnings

Stock Alert! Mindtree beats street estimates in Q1, Morgan Stanley bets big on the stock

Stock Alert! This tech stock is up 150% and Morgan Stanley says rally is not over after it delivers hot Q1 earnings.

Mindtree Earnings Boost

Mindtree reported revenue growth of 7.6% , EBIT margin at 17.7% both beating street estimates.&nbsp;

Mindtree&nbsp;delivered strong set of Q1 numbers that beat street estimates,&nbsp; with cross currency revenue growth of 7.6% (QoQ). Morgan Stanley says there is more upside left to the stock that has seen a 150% rise in the last 1 year. Morgan Stanley Bets on Mindtree
<ul>
<li>Retain Overweight on stock, Price target of Rs 2800/share</li>
<li>Revenue growth and margins were stronger than expected</li>
<li>Deal wins of $504mn were the&nbsp;strongest the company has ever seen</li>
<li>Strongest ever headcount addition of 3400 in Q1</li>
</ul>
Read/Watch Also: <a href="https://www.edtr.ai/9vcq" target="_blank">All eyes on Infosys, how to trade the earnings</a>

The anchor investors for Zomato's IPO&nbsp;queued up around the block to order off the IPO menu for the food tech giant.&nbsp;Food delivery giant Zomato on July 13 raised Rs 4,196.51 crore from 186 anchor investors ahead of IPO opening.Read/Watch Also: Zomato&nbsp;IPO&nbsp;opens, is it too pricey?Investors who participated in the anchor book include names like New World Fund Inc, American Funds, Tiger Global Investments Fund, BlackRock Global, Lansforsakringar Asienfond. The anchor investors have bid for the shares&nbsp;at the higher price band of Rs 76/share.&nbsp;Click here to know how to apply for the IPO&nbsp;on Paytm&nbsp;Money

Zomato IPO | Anchors order 30x of offer, anchor book raises Rs 4,196 cr from 186 anchor investors

Anchor investors line up around the around the block for Zomato&nbsp;IPO. 30 times the demand from a list of 186 investors for the food tech giant IP0.&nbsp;

Zomato IPO anchor book

Reports indicate&nbsp;anchor book saw over 30x more demand than the shares on offer., total interest generated was in excess of Rs 1 trillion.&nbsp;

The anchor investors for Zomato's IPO&nbsp;queued up around the block to order off the IPO menu for the food tech giant.&nbsp;Food delivery giant Zomato on July 13 raised Rs 4,196.51 crore from 186 anchor investors ahead of IPO opening. Read/Watch Also: <a href="https://www.edtr.ai/9v99">Zomato&nbsp;IPO&nbsp;opens, is it too pricey?</a> Investors who participated in the anchor book include names like New World Fund Inc, American Funds, Tiger Global Investments Fund, BlackRock Global, Lansforsakringar Asienfond. The anchor investors have bid for the shares&nbsp;at the higher price band of Rs 76/share.&nbsp; Click here <a href="https://www.edtr.ai/9tvv">to know how to apply for the IPO&nbsp;on Paytm&nbsp;Money</a>

Jubilant Foodworks, the owner of the Domino's Pizza franchise in India has brokerages raising their target on the stock after a hot set of Q4 earnings.&nbsp;Jubilant Foodworks reported better-than-expected Q4 results with net profit zooming 359% at Rs 104 cr. Brokerages like CLSA&nbsp;are confident of a better return from the stock going ahead as the management has seen a division and new hires to manage the wider portfolio better.&nbsp;The company hired Gaurav Pandey from HUL to head its Popeyes business and appointed a new CFO, Ashish Goenka, who previously worked at HUL and Airtel.These changes and outlook has prompted prompted brokerages to raise targets across the board. Here are what the brokerages are betting now betting on&nbsp;

HSBC: Revised target at Rs&nbsp;3550 from Rs 3300&nbsp;
CLSA: Revised price target at Rs&nbsp;3300 from Rs 3000&nbsp;
JPMorgan:&nbsp;Revised price target at Rs&nbsp;3425 from Rs 3030



Jubilant Food Q4: Why brokerages expect this stock to have a hot return

Jubilant Foodworks, the owner of the Domino's Pizza franchise in India has brokerages raising their target on the stock after a hot set of Q4 earnings.&nbsp; Jubilant Foodworks reported better-than-expected Q4 results with net profit zooming 359% at Rs 104 cr. Brokerages like CLSA&nbsp;are confident of a better return from the stock going ahead as the management has seen a division and new hires to manage the wider portfolio better.&nbsp;The company hired Gaurav Pandey from HUL to head its Popeyes business and appointed a new CFO, Ashish Goenka, who previously worked at HUL and Airtel. These changes and outlook has prompted prompted brokerages to raise targets across the board. Here are what the brokerages are betting now betting on&nbsp;
<ul>
<li>HSBC: Revised target at Rs&nbsp;3550 from Rs 3300&nbsp;</li>
<li>CLSA: Revised price target at Rs&nbsp;3300 from Rs 3000&nbsp;</li>
<li>JPMorgan:&nbsp;Revised price target at Rs&nbsp;3425 from Rs 3030</li>
</ul>

Jubilant Foodworks, the owner of the Domino's Pizza franchise in India has brokerages raising their target on the stock after a hot set of Q4 earnings.&nbsp; Jubilant Foodworks reported better-than-expected Q4 results with net profit zooming 359% at Rs 104 cr. Brokerages like CLSA&nbsp;are confident of a better return from the stock going ahead as the management has seen a division and new hires to manage the wider portfolio better.&nbsp;The company hired Gaurav Pandey from HUL to head its Popeyes business and appointed a new CFO, Ashish Goenka, who previously worked at HUL and Airtel. These changes and outlook has prompted prompted brokerages to raise targets across the board. Here are what the brokerages are betting now betting on&nbsp;
<ul>
<li>HSBC: Revised target at Rs&nbsp;3550 from Rs 3300&nbsp;</li>
<li>CLSA: Revised price target at Rs&nbsp;3300 from Rs 3000&nbsp;</li>
<li>JPMorgan:&nbsp;Revised price target at Rs&nbsp;3425 from Rs 3030</li>
</ul>

India's largest bank is the star of Dalal&nbsp;Street hitting a new record high and closing in on Rs 4 lakh crore&nbsp;marketcap&nbsp;and brokerages believe there is still a lot of steam left in the stock.&nbsp;CLSA&nbsp;who has been bullish on the stock from August believes the 55% rally this year could extend further. The brokerage is reiterating their BUY target with a price target of&nbsp;Rs 650/share which offers a&nbsp;+50% upside from the current levels.&nbsp;SBI&nbsp;is up 150% from it's one year low of Rs 175/sh and has outperformed other banking peers by 40-70%.&nbsp;

Stock Spotlight SBI: Stock at record high, CLSA sees 50% upside

Stock Spotlight SBI: Stock at record high, CLSA sees 50% upside as the company closes in on 4 lakh crore&nbsp;marketcap.&nbsp;

India's largest bank is the star of Dalal&nbsp;Street hitting a new record high and closing in on Rs 4 lakh crore&nbsp;marketcap&nbsp;and brokerages believe there is still a lot of steam left in the stock.&nbsp; CLSA&nbsp;who has been bullish on the stock from August believes the 55% rally this year could extend further. The brokerage is reiterating their BUY target with a price target of&nbsp;Rs 650/share which offers a&nbsp;+50% upside from the current levels.&nbsp; SBI&nbsp;is up 150% from it's one year low of Rs 175/sh and has outperformed other banking peers by 40-70%.&nbsp;

brokerage calls

Categories